166 related articles for article (PubMed ID: 23028998)
1. Interferon regulatory factor-8 is important for histone deacetylase inhibitor-mediated antitumor activity.
Banik D; Khan AN; Walseng E; Segal BH; Abrams SI
PLoS One; 2012; 7(9):e45422. PubMed ID: 23028998
[TBL] [Abstract][Full Text] [Related]
2. IFN regulatory factor 8 mediates apoptosis in nonhemopoietic tumor cells via regulation of Fas expression.
Yang D; Thangaraju M; Browning DD; Dong Z; Korchin B; Lev DC; Ganapathy V; Liu K
J Immunol; 2007 Oct; 179(7):4775-82. PubMed ID: 17878376
[TBL] [Abstract][Full Text] [Related]
3. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways.
Hrgovic I; Doll M; Kleemann J; Wang XF; Zoeller N; Pinter A; Kippenberger S; Kaufmann R; Meissner M
BMC Cancer; 2016 Sep; 16(1):763. PubMed ID: 27716272
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma.
Tiper IV; Webb TJ
Cancer Immunol Immunother; 2016 Nov; 65(11):1411-1421. PubMed ID: 27614429
[TBL] [Abstract][Full Text] [Related]
5. The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells.
Park KC; Heo JH; Jeon JY; Choi HJ; Jo AR; Kim SW; Kwon HJ; Hong SJ; Han KS
BMC Cancer; 2015 Jan; 15():19. PubMed ID: 25613585
[TBL] [Abstract][Full Text] [Related]
6. Host immunosurveillance controls tumor growth via IFN regulatory factor-8 dependent mechanisms.
Greeneltch KM; Schneider M; Steinberg SM; Liewehr DJ; Stewart TJ; Liu K; Abrams SI
Cancer Res; 2007 Nov; 67(21):10406-16. PubMed ID: 17974984
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of histone deacetylase activity suppresses IFN-γ induction of tripartite motif 22 via CHIP-mediated proteasomal degradation of IRF-1.
Gao B; Wang Y; Xu W; Li S; Li Q; Xiong S
J Immunol; 2013 Jul; 191(1):464-71. PubMed ID: 23729439
[TBL] [Abstract][Full Text] [Related]
8. Interferon-gamma induces regression of epithelial cell carcinoma: critical roles of IRF-1 and ICSBP transcription factors.
Egwuagu CE; Li W; Yu CR; Che Mei Lin M; Chan CC; Nakamura T; Chepelinsky AB
Oncogene; 2006 Jun; 25(26):3670-9. PubMed ID: 16462767
[TBL] [Abstract][Full Text] [Related]
9. Combining PCI-24781, a novel histone deacetylase inhibitor, with chemotherapy for the treatment of soft tissue sarcoma.
Lopez G; Liu J; Ren W; Wei W; Wang S; Lahat G; Zhu QS; Bornmann WG; McConkey DJ; Pollock RE; Lev DC
Clin Cancer Res; 2009 May; 15(10):3472-83. PubMed ID: 19417021
[TBL] [Abstract][Full Text] [Related]
10. IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.
Armstrong MJ; Stang MT; Liu Y; Yan J; Pizzoferrato E; Yim JH
Cancer Biol Ther; 2015; 16(7):1029-41. PubMed ID: 26011589
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activities and on-target toxicities mediated by a TRAIL receptor agonist following cotreatment with panobinostat.
Martin BP; Frew AJ; Bots M; Fox S; Long F; Takeda K; Yagita H; Atadja P; Smyth MJ; Johnstone RW
Int J Cancer; 2011 Jun; 128(11):2735-47. PubMed ID: 20715169
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist.
Frew AJ; Lindemann RK; Martin BP; Clarke CJ; Sharkey J; Anthony DA; Banks KM; Haynes NM; Gangatirkar P; Stanley K; Bolden JE; Takeda K; Yagita H; Secrist JP; Smyth MJ; Johnstone RW
Proc Natl Acad Sci U S A; 2008 Aug; 105(32):11317-22. PubMed ID: 18685088
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of interferon regulatory factor-1 expression results in predominance of cell growth stimulatory effects of interferon-gamma due to phosphorylation of Stat1 and Stat3.
Sato T; Selleri C; Young NS; Maciejewski JP
Blood; 1997 Dec; 90(12):4749-58. PubMed ID: 9389691
[TBL] [Abstract][Full Text] [Related]
14. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor.
Hsieh YJ; Hwu L; Chen YC; Ke CC; Chen FD; Wang HE; Lin KP; Yeh HH; Chang CW; Liu RS
J Nucl Med; 2014 Apr; 55(4):678-85. PubMed ID: 24639460
[TBL] [Abstract][Full Text] [Related]
15. A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Hwang JJ; Kim YS; Kim T; Kim MJ; Jeong IG; Lee JH; Choi J; Jang S; Ro S; Kim CS
Invest New Drugs; 2012 Aug; 30(4):1434-42. PubMed ID: 21773733
[TBL] [Abstract][Full Text] [Related]
16. Death by histone deacetylase inhibitor quisinostat in tongue squamous cell carcinoma via apoptosis, pyroptosis, and ferroptosis.
Wang X; Liu K; Gong H; Li D; Chu W; Zhao D; Wang X; Xu D
Toxicol Appl Pharmacol; 2021 Jan; 410():115363. PubMed ID: 33290780
[TBL] [Abstract][Full Text] [Related]
17. Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells.
An X; Wei Z; Ran B; Tian H; Gu H; Liu Y; Cui H; Zhu S
Anticancer Agents Med Chem; 2020; 20(17):2114-2124. PubMed ID: 32593284
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors induce cell death selectively in cells that harbor activated kRasV12: The role of signal transducers and activators of transcription 1 and p21.
Klampfer L; Huang J; Shirasawa S; Sasazuki T; Augenlicht L
Cancer Res; 2007 Sep; 67(18):8477-85. PubMed ID: 17875686
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
[TBL] [Abstract][Full Text] [Related]
20. IRF5 is elevated in childhood-onset SLE and regulated by histone acetyltransferase and histone deacetylase inhibitors.
Shu J; Li L; Zhou LB; Qian J; Fan ZD; Zhuang LL; Wang LL; Jin R; Yu HG; Zhou GP
Oncotarget; 2017 Jul; 8(29):47184-47194. PubMed ID: 28525378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
